HbA 1c has been described as insensitive for diabetes screening compared with the oral glucose tolerance test (OGTT) in CF ( 5, 8). However, studies of the association between HbA 1c and average glucose in individuals with cystic fibrosis (CF) have been limited, and there is controversy surrounding the utility of HbA 1c in individuals with CF ( 5– 7). The Diabetes Control and Complications Trial (DCCT) and Epidemiology of Diabetes Interventions and Complications (EDIC) follow-up study have also demonstrated clear correlations between HbA 1c and the development of microvascular and macrovascular complications in these populations ( 3, 4). A strong linear relationship between average glucose and hemoglobin A 1c (HbA 1c) in adults with type 1 and type 2 diabetes ( 1, 2) has been well described.
0 kommentar(er)
